Efficacy News and Research

RSS

New drug therapies that target glutamate pathway may be effective for subgroups of patient with schizophrenia

Mounting evidence indicates that disturbances in the brain's glutamate pathway contribute to symptoms of schizophrenia. Thus, the glutamate pathway has become the target of a number of new drug therapies. Findings published in the journal Biological Psychiatry suggest that at least one of these drugs may be an effective treatment for individuals in the early course of the illness.

9 Dec 2015

Novel antidepressant appears to be safe, effective against depression in clinical trial

A small clinical trial of a novel antidepressant that stimulates neurogenesis - the production of new brain cells - shows that the compound appears to be safe and may be effective against depression.

9 Dec 2015

FDA approves recombinant von Willebrand factor for treating bleeding episodes in adults with VWD

The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed with VWD.

8 Dec 2015

Oxitec prepares to increase supplies of OX513A to address recent outbreak of Zika virus in Brazil

Intrexon Corporation, a leader in synthetic biology, today announced that Oxitec, a UK-based subsidiary of the Company, is prepared to increase supplies of its proprietary mosquito control solution, OX513A, through its Brazil facilities to assist Brazil in addressing the recent devastating outbreak of the Zika virus and other diseases transmitted by the Aedes aegypti mosquito.

8 Dec 2015

Bionomics plans to launch BNC210 Phase 2 trial for treatment of PTSD

Australian drug development company Bionomics Limited will launch a key Phase 2 trial of its novel anxiety drug BNC210 as a treatment for post-traumatic stress disorder (PTSD), following a US$12 million private placement to US institutional investors.

8 Dec 2015

Kanuma approved as first treatment for patients with LAL deficiency

Today, the U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.

8 Dec 2015

New way to antagonize human nuclear receptor

On Monday 7 December the journal Nature Communications published the research findings of Eindhoven University of Technology (TU/e), Merck Research Laboratories (Merck is known as MSD outside the US and Canada) and Leiden University concerning an entirely new way of antagonizing a human nuclear receptor.

8 Dec 2015

Simple approach to predict viral evolution may improve vaccine efficacy

New results from a study performed at the University of Helsinki suggest that genomic information from circulating influenza viruses can help in producing more efficient seasonal vaccines. The researchers were able to develop a simple approach for reliable real-time tracking and prediction of viral evolution based on whole-genome sequences of influenza viruses.

8 Dec 2015

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

The Dompé biopharmaceutical company announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth Factor (rhNGF) - the investigational biotech molecule developed by Dompé based on research by Nobel Laureate Rita Levi Montalcini - as an orphan drug for the treatment of neurotrophic keratitis.

8 Dec 2015

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a license and option agreement with Pfizer Inc. to advance the development and commercialization of a new class of antibody therapeutics based on BioAtla's CAB platform and utilizing Pfizer's proprietary antibody drug conjugate (ADC) payloads.

8 Dec 2015

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Amgen today announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO (blinatumomab) in adults with acute lymphoblastic leukemia (ALL).

8 Dec 2015

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma.

8 Dec 2015

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).

8 Dec 2015

Motivational interviewing helps curb prescription opioid abuse among older adults with chronic pain

Prescription opioid abuse has reached epidemic proportions, with more than half of patients being treated for chronic pain reportedly misusing their medication at some point.

8 Dec 2015

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers.

7 Dec 2015

Gene therapy shows promise in children with Wiskott-Aldrich syndrome

Researchers reported promising preliminary outcomes for the first four children enrolled in a U.S. gene therapy trial for Wiskott-Aldrich syndrome (WAS), a life-threatening genetic blood and immune disorder, at the 57th annual meeting of the American Society of Hematology (abstract #260).

7 Dec 2015

Age doesn't matter when considering HCT for patients with MDS, study reveals

Results from a prospective study of 1,280 patients with myelodysplastic syndrome (MDS) showed that survival at 100 days and at two years following hematopoietic cell transplant (HCT) for patients aged 65 and older is comparable to patients aged 55 to 64.

7 Dec 2015

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer.

7 Dec 2015

Potential for chemotherapy-free standard of care in advanced mantle cell lymphoma

The combination of ibrutinib and rituximab shows activity in patients with relapsed or refractory mantle cell lymphoma, suggests research published in The Lancet Oncology.

2 Dec 2015

Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie

A phage is a virus that infects a bacterium. People often get very confused about what the difference is between a virus and a bacterium. A virus, like a bacterium, is also a microorganism, but unlike bacteria, it needs to have a host to be able to replicate and propagate.

2 Dec 2015

Efficacy News and Research

New drug therapies that target glutamate pathway may be effective for subgroups of patient with schizophrenia

Novel antidepressant appears to be safe, effective against depression in clinical trial

FDA approves recombinant von Willebrand factor for treating bleeding episodes in adults with VWD

Oxitec prepares to increase supplies of OX513A to address recent outbreak of Zika virus in Brazil

Bionomics plans to launch BNC210 Phase 2 trial for treatment of PTSD

Kanuma approved as first treatment for patients with LAL deficiency

New way to antagonize human nuclear receptor

Simple approach to predict viral evolution may improve vaccine efficacy

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Motivational interviewing helps curb prescription opioid abuse among older adults with chronic pain

New approaches to treating leukemia, lymphoma and myeloma

Gene therapy shows promise in children with Wiskott-Aldrich syndrome

Age doesn't matter when considering HCT for patients with MDS, study reveals

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

Potential for chemotherapy-free standard of care in advanced mantle cell lymphoma

Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News